When PrEP fails. Laura Waters MD FRCP Mortimer Market Centre London
|
|
- Jennifer Merritt
- 5 years ago
- Views:
Transcription
1 When PrEP fails Laura Waters MD FRCP Mortimer Market Centre London
2
3 PrEP works If people at risk take it If it s taken in the right way If it s available Commissioned/licensed Affordable Supported
4 But. European PrEP coverage ranges from non-existent to low We do not know if wide scale roll-out will be feasible We do not know if intermittent-intermittent PrEP will be effective Prevention is better than cure But right now we have too little of one and none of the other!
5 EPIDEMIOLOGY
6 Diagnosed HIV in the EU/EEA & WHO European Region* ,000 new cases in 2014 highest since reporting started in 1980s *excluding Russia European Centre for Disease Prevention and Control, WHO Regional Office for Europe. HIV/AIDS surveillance in Europe Stockholm: ECDC;
7 PHE: New HIV Diagnoses HIV New Diagnoses, Treatment and Care in the UK: 2015 report 3,360 2,490
8 IMPROVING DIAGNOSIS
9 Globally 54% of HIV is UNDIAGNOSED Of 35 million people living with HIV 19 million do not know their status
10 Cascades Raymond A et al. Journal of the International AIDS Society 2014, 17(Suppl 3):19507
11 Estimated number PLWH UK 2014: diagnosed and undiagnosed Overall: 18% % undiagnosed has declined Men who have sex with men: 14% Black more African than heterosexuals: the numbers 12-15% Other heterosexuals: 29-31%
12 Implications of undiagnosed HIV Undiagnosed HIV Individual Late presentation Illness Death Society Transmission Costs of advanced disease Prevention Prevention efforts must include testing
13 Late diagnosis Definition: Late presentation: Persons presenting for care with CD4 <350 or and AIDS-defining event, regardless of CD4 Presentation with advanced HIV disease: Persons presenting for care with <200 an AIDS-defining event, regardless of CD4 cell count Almost 50% across Europe are diagnosed late Declining cases of AIDS across Europe but in /3 AIDS conditions in newly or recently diagnosed Antinori A et al. HIV Medicine 2010
14 Late diagnosis
15 Late diagnosis in the UK by risk group CD4 <350 within 3 months of diagnosis 28% >50% >50%
16 UK: late diagnosis over time
17 Issues associated with late presentation Transmission Health care costs Increased mortality UK: ten-fold increased risk of death within 1 year of HIV diagnosis if late vs prompt (3.8% vs. 0.35%) Impact of AIDS diagnoses on mortality and long-term co-morbidity risk Legacy effect of immunosuppression and prolonged viraemia
18 Risk factors & reasons for late diagnosis Risk factors Older age Heterosexual Non-national Male Reasons Testing (1 st test for 32-55%) Risk perception Feeling well Stigma, fear, migration status Lack of access Lack of offer
19 Risk factors & reasons for late diagnosis Risk factors Older age Heterosexual Non-national Male Reasons Testing (1 st test for 32-55%) Risk perception Feeling well Stigma, fear, migration status Lack of access Lack of offer
20 PrEP & perception of risk Validated risk assessment 420 MSM in Toronto Of men at objective high risk: 68.3% did not perceive themselves to be at moderate to high risk 23.6% unaware of PrEP 40.1% not willing to use PrEP 47.6% lacked a family physician with whom they felt comfortable discussing sexual health 31.6% had no means to cover the cost of PrEP Wilton J et al. J Int AIDS Soc 2016 Jun; 19(1): 20777
21 Risk factors & reasons for late diagnosis Risk factors Older age Heterosexual Non-national Male Reasons Testing (1 st test for 32-55%) Risk perception Feeling well Stigma, fear, migration status Lack of access Lack of offer
22 European HIV testing guidelines
23 Who to test? Risk groups People attending higher risk clinical services People with conditions suggestive of HIV Routine testing
24 Who to test? Risk groups MSM, IDU, people from high prevalence areas People attending higher risk clinical services Sexual health, TOP, DDU, hepatitis, oncology People with conditions suggestive of HIV AIDS-defining illnesses, indicator diseases Routine testing eg. all medical admissions and primary care registrations where HIV prevalence >2/1000 (UK)
25 accessed 27/02/2016 Indicator conditions
26 HIV prevalence by indicator condition 0.1% and LL 95%CI>0.1% % CI > 95% CI > % 95% CI CI < 0.1 Test ed HIV Slide courtesy of Dr. Michael Rayment
27 Overcoming barriers Access Testing in more settings, skilling all health workers Stigma Knowledge, home testing, non-sexual health clinics Pre-test counselling Quick, simple, verbal, assess risk & window periods Anxiety Extra support, rapid testing (point of care)
28 ECDC guidance
29 TREATMENT
30 Benefits of ART Individual Population Improved life expectancy Reduced morbidity Reduced risk to partners Lower health care costs Better productivity Reduced transmission
31 START: Primary results Median CD4 at ART 408 Median CD4 at ART 651 (95% confidence interval [CI], 0.30 to 0.62; P<0.001) n=2,359 n=2, Lundgren D, et al. IAS Vancouver, CAN. Oral # MOSY03; 2. Lundgren D, et al. NEJM 2015 Published Epub ahead of print July 20, 2015 DOI: /NEJMoa
32 START: AIDS vs non-aids related events Kaplan Meier estimates of the cumulative percentage of patients with a composite primary endpoint Serious AIDS-related events HR 0.28 (95% CI, 0.15 to 0.50; P<0.001) Serious non-aids-related events HR 0.61 (95% CI, 0.38 to 0.97; P=0.04) INSIGHT START Study Group. NEJM 2015;373:
33 When to start IAS-USA 1 DHHS 2 WHO 3 EACS 4 BHIVA 5 ART is recommended for treatment of HIV infection and prevention of transmission of HIV regardless of CD4 cell count (AIa-BIII) ART recommended for all regardless of pretreatment CD4. Strength of recommendation A1 (strong recommendation based on RCT) for all Start ART in all regardless of WHO clinical stage or CD4. Prioritise severe/advance clinical disease (WHO stage 3 or 4) and adults with CD4 350 ART should always be recommended irrespective of the CD4 count. Strong recommendation if CDC B or C (including TB) or CD4 <350 All people living with HIV should start ART 1. Günthard et al, JAMA, 2014; /05/2016; /05/2016; /05/2016; /05/2016.
34 START: sub-studies & subgroups Sub-studies: Liver: annual fibroscan data pending Cardiovascular: no difference in arterial elasticity Pulmonary: no difference in impact on lung function Neurocognitive: no difference in rates of NCI Bone: more hip/spine bone loss in immediate arm Subgroups (IAS 2016): Benefit of immediate ART attenuated/negated if: age <50, CD4 >800, CD4:CD8 ration >0.8, Framingham <1% and, particularly, VL <3000,
35 Treatment as prevention: serodifferent couples HPTN % reduced transmissions initially 93% reduction in final analysis: 8 transmissions in ART arm 4 virological failures 4 prior to suppressions PARTNER 16,400 CLSA in MSM and 28,000 CLSA in heterosexuals = ZERO transmissions (estimated 86 if HIV+ partner not on suppressive ART) 1. Cohen MS et al. N Engl J Med. 2011; 2.Cohen MS et al. IAS 2015 MOAC0106LB; 3. Eshleman SH et al. IAS 2015 MOAC0106LB; 4. Rodger A et al. CROI O153LB.
36 Final results 888 couples (340 MSM, 548 heterosexual) Couples had already been having CLSI for an average of 2 years before entering the study During study there were 58,213 condomless sex acts 20% of the reported anal sex was in heterosexuals ZERO TRANSMISSIONS FROM PRIMARY PARTNERS!! 11 transmissions from other partners Rodger A et al. JAMA Jul 12;316(2): doi: /jama
37 Caveats Confidence intervals Narrower than at 2014 analysis Upper limit of 95% CI: 0.3% overall, 1% for anal sex in MSM where HIV+ partner insertive/top Higher estimated risk if +VL: 2.23% overall, 2.7% in MSM Author conclusion: We can fairly safely say that the chance of transmission from a virally suppressed HIV+ person during heterosexual sex is negligible However, we need to collect more data on gay men before saying this with the same degree of certainty Rodger A et al. JAMA Jul 12;316(2): doi: /jama
38 Caveats from accompanying JAMA editorial People in stable relationships may not reflect all PLWH Consistent with findings from some PreP studies eg. PARTNERS PrEP vs VOICE & TDF-2 HIV+ participants had been on ART for average 7.5Y High self-reported adherence High levels STI screening + advice HIV- partners were still HIV- despite 2 years CLSI prior to study entry Daar E, Corado K. JAMA Jul 12;316(2)
39 Test & Treat Examples of great success Africa USA London But.
40 ANRS First major study of test & treat approach KwaZulu-Natal where 30% are HIV+ (highest in SA) Cluster RCT Each cluster = geographical area of about 1000 residents 11 intervention clusters, 11 controls Intervention Whole population over age 16 in both groups offered home-based HIV testing every 6/12 Intervention clusters offered immediate ART, control according to national guidelines IAS 2016
41 Results 28,153 in study population, average age 30, 63% F 31% already living with HIV (34% of those on ART) 88% tested at least once If diagnosed HIV+ linkage poor: 28% had attended ART clinic by 3 months 36% by 6 months 47% by 12 months ALMOST IDENTICAL IN THE TWO GROUPS IAS 2016
42 ANRS TasP - Estimated cascade of care UNAIDS target TasP trial (1 st January 2016) Control Intervention IAS
43 New HIV infections 2.21% per year (2.13% intervention clusters vs 2.27% controls) Further analyses required to explain lack of engagement in care Was the intervention sufficient? Community attitudes & stigma? IAS 2016
44 CONCLUSIONS
45 What we know People who are diagnosed, in care and on treatment do very well Our challenges are to improve diagnosis and improve prevention Treatment as prevention will reduce but not eliminate HIV transmission as long as PLWH remain undiagnosed Variable data regarding population impact of TasP
46 % UK MSM epidemic & limitations of TasP
47
48 100% 80% 60% 40% 20% 0% Global Estimates ( ) vs the Gap 36.9 million to reach Targets Breakpoint 1: 13.4 million Undiagnosed Breakpoint 2: 14.9 million not treated 53% 19.8 million 41% 15.0 million 32%* 11.6* million HIV Positive People Diagnosed On ART Viral Suppression <1000 (ITT)* Ref: On ART = March How Aids Changed Everything. Fact Sheet. UNAIDS MDG 6: 15 YEARS, 15 LESSONS OF HOPE FROM THE AIDS RESPONSE July * Average viral suppression% Intention to Treat LMIC rate from a Systematic Review by McMahon J. et al. Viral suppression after 12 months of antiretroviral therapy in low-and middle-income countries: a systematic review." Bulletin of the World Health Organization 91.5 (2013): Breakpoint 3: 15.3 million Not Virally Supressed
49 Test and Treat plus PrEP access since 2013 (estimate 15% HIV- MSM taking PrEP) Discussion of PrEP mandatory in public school 9 th grade classes Of 657 c/o PrEP no new diagnoses HIV (Kaiser P) New diagnoses HIV 2332 in 1992 vs 302 in 2014 Volk CID Nov 2015
50 Summary PrEP works ART works Combined approaches = SUCCESS
51 Thank
HIV in Laura Waters Consultant Physician CNWL, Mortimer Market Centre, London
HIV in 2016 Laura Waters Consultant Physician CNWL, Mortimer Market Centre, London Content HIV epidemiology HIV testing Antiretroviral therapy Benefits of early treatment & when to start What to start
More informationStrategic use of antiretroviral drugs to prevent HIV transmission
Strategic use of antiretroviral drugs to prevent HIV transmission 22th Tunisian Congress of Infectious Diseases 2nd Congress of Federation of Arab Societies of Clinical Microbiology and Infectious Diseases
More informationFertility Desires/Management of Serodiscordant HIV + Couples
Fertility Desires/Management of Serodiscordant HIV + Couples William R. Short, MD, MPH Assistant Professor of Medicine Division Of Infectious Diseases Jefferson Medical College of Thomas Jefferson University
More informationImplementation of testing (and other interventions along the Continuum of Care)
Implementation of testing (and other interventions along the Continuum of Care) Jonathan Mermin, MD, MPH National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention U.S. Centers for Disease Control
More informationTreat All : From Policy to Action - What will it take?
Strategy Finance Integration Cascade of services People centred Political Will Treat All : From Policy to Action - What will it take? Thursday, 9 June, 13.00 14.30 Conference Room 11, United Nations Questions
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationUsing anti-hiv drugs for prevention
Using anti-hiv drugs for prevention Highlights from AIDS 2012 (and 2 nd International Workshops on Treatment as Prevention) Tim Rogers, trogers@catie.ca Using anti-hiv Drugs for Prevention Outline Treatment
More informationSeble G. Kassaye, M.D., M.S. Assistant Professor of Medicine Division of Infectious Diseases and Travel Medicine Georgetown University
Seble G. Kassaye, M.D., M.S. Assistant Professor of Medicine Division of Infectious Diseases and Travel Medicine Georgetown University November 5, 2016 None HIV epidemiology Global U.S. Washington, D.C.
More informationHIV in the United Kingdom
HIV in the United Kingdom Valerie Delpech and Alison Brown on behalf of the HIV and AIDS Reporting Section National Infection Service Public Health England Released 15 December 2017 Undetectable=Untransmittable
More informationHIV & AIDS IN SOUTH AFRICA: WHERE ARE WE AND WHAT ARE
HIV & AIDS IN SOUTH AFRICA: WHERE ARE WE AND WHAT ARE THE REMAINING CHALLENGES DR YOGAN PILLAY, NDOH SA HIV CLINICIANS SOCIETY CONFERENCE, CAPE TOWN 25 NOVEMBER, 2012 GLOBAL DATA 34m people living with
More informationState of the Art for ART for Prevention. Wafaa El-Sadr, MD, MPH ICAP-Columbia University
State of the Art for ART for Prevention Wafaa El-Sadr, MD, MPH ICAP-Columbia University Millions Global Scale-Up of HIV Treatment 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 End of 2002 End of 2003 End of 2004
More informationZero HIV infections Zero HIV deaths Zero HIV stigma. Stephanie Cohen, MD, MPH on behalf of the Getting to Zero Consortium
Zero HIV infections Zero HIV deaths Zero HIV stigma Stephanie Cohen, MD, MPH on behalf of the Getting to Zero Consortium Number of New HIV Diagnoses Overall decline in new HIV diagnoses and death in San
More informationCan we treat our way out of the HIV epidemic?
Can we treat our way out of the HIV epidemic? Richard E. Chaisson, MD Center for AIDS Research Center for TB Research Johns Hopkins University Schoolboy s (and politician s) tricks for evading the question
More informationTreatment as Prevention
Optimizing the Impact of ART Treatment as Prevention A Made-in-BC Strategy to End the AIDS Pandemic Julio Montaner, OC, OBC, MD Professor of Medicine and Head, Division of AIDS, University of British Columbia
More informationGovernment of Canada Federal AIDS Initiative Milestones
HIV in Canada: Trends and Issues for Advancing Prevention, Care, Treatment and Support Through Knowledge Exchange Michael R Smith, Senior Policy Advisor, Programs and Coordination Division, Centre for
More informationTreatment as Prevention
Treatment as Prevention The Key to an AIDS-Free Generation Julio Montaner MD, DSc(hon), FRCPC, FCCP, FRSC, OBC Director, BC-Centre for Excellence in HIV/AIDS, Providence Health Care Professor of Medicine
More informationCombination prevention: Public health and human rights imperatives
Combination prevention: Public health and human rights imperatives Gottfried Hirnschall, MD MPH HIV/AIDS Department WHO, Geneva London, June 11, 2012 Outline The epidemic and response What is combination
More information2020 Vision: making England s HIV prevention response the best in the world
DISCUSSION PAPER 2020 Vision: making England s HIV prevention response the best in the world Introduction Effective HIV prevention makes good public health and economic sense. HIV remains one of the fastest-growing
More informationProgram to control HIV/AIDS
90-90-90 Program to control HIV/AIDS Hamid Sharifi Associate Professor in Epidemiology [sharifihami@gmail.com] 1 Targets for ending the AIDS epidemic 2 New HIV infections in low- and middle-income countries,
More informationJulio Montaner MD, DSc(hon), FRCPC, FCCP, FRSC, OBC
Julio Montaner MD, DSc(hon), FRCPC, FCCP, FRSC, OBC Director, BC-Centre for Excellence in HIV/AIDS, Providence Health Care Professor of Medicine and Head, Division of AIDS, University of British Columbia
More informationHigh Impact Prevention: Science, Practice, and the Future of HIV
High Impact Prevention: Science, Practice, and the Future of HIV Jonathan Mermin, MD, MPH National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Centers for Disease Control and Prevention
More informationTreatment as prevention (TasP) Can treatment reduce the transmission of HIV: Experience from the UK
Treatment as prevention (TasP) Can treatment reduce the transmission of HIV: Experience from the UK Dr Valerie Delpech Health Protection Agency, London (Public Health England) Outline! Brief overview Science,
More informationDidactic Series. Update on DHHS Guidelines for HIV Treatment: Adherence to the Care Continuum
Didactic Series Update on DHHS Guidelines for HIV Treatment: Adherence to the Care Continuum Daniel Lee, MD UCSD Medical Center Owen Clinic March 8 th, 2018 1 Adherence to the Care Continuum Revised from
More informationBHIVA Workshop: When to Start. Dr Chloe Orkin Dr Laura Waters
BHIVA Workshop: When to Start Dr Chloe Orkin Dr Laura Waters Aims To use cases to: Review new BHIVA guidance Explore current data around when to start To discuss: Medical decisions, pros and cons Luigi
More informationHIV and Paediatrics in Central Europe
2nd Central and Eastern European Meeting on Viral Hepatitis and Co-Infection with HIV HIV and Paediatrics in Central Europe Mariana Mărdărescu MD PhD Consultant in Infectious Diseases Senior Doctor in
More informationWhere are we going after effectiveness studies?
Where are we going after effectiveness studies? Nyaradzo M. Mgodi (MBChB, MMed) UZ-UCSF Collaborative Research Program Harare, Zimbabwe MTN Annual Meeting 28 March 2011, Arlington, VA Introduction 30 years
More informationImproving outcomes The UK s achievements in managing and preventing the HIV epidemic and how we should approach public health priorities
Improving outcomes The UK s achievements in managing and preventing the HIV epidemic and how we should approach public health priorities Professor Kevin Fenton Senior Advisor, Public Health England Director,
More informationHIV transmission in the UK within Black African communities: how common is it and how do we prevent it? Dr Valerie Delpech
HIV transmission in the UK within Black African communities: how common is it and how do we prevent it? Dr Valerie Delpech We gratefully acknowledge persons living with HIV, clinicians, health advisors,
More informationOR: Steps you can take in the clinic to prevent HIV infections
Implementing Changes to Reduce HIV Incidence: Synergies between Public Health and Primary Care Kevin Ard, MD, MPH Brigham and Women s Hospital, Massachusetts General Hospital, and the Fenway Institute
More informationHIV TREATMENT AS PREVENTION THE KEY TO AN AIDS-FREE GENERATION
HIV TREATMENT AS PREVENTION THE KEY TO AN AIDS-FREE GENERATION Adeeba Kamarulzaman Professor of Medicine University of Malaya Executive Council Member International AIDS Society Since the beginning of
More informationState of Alabama HIV Surveillance 2014 Annual Report
State of Alabama HIV Surveillance 2014 Annual Report Prepared by: Division of STD Prevention and Control HIV Surveillance Branch Contact Person: Richard P. Rogers, MS, MPH richard.rogers@adph.state.al.us
More informationStuck : Contextualizing the U.S. HIV epidemic among black MSM. Greg Millett amfar April 2, 2015
Stuck : Contextualizing the U.S. HIV epidemic among black MSM Greg Millett amfar April 2, 2015 New HIV Infections, 2010 2008-2010 Women: 21% decrease MSM: 12% increase Young MSM: 22% increase Lifetime
More informationWho is a migrant? 12/10/2018. HIV and migrants. Heterogeneous groups of persons with different migration drivers
HIV and migrants Julia del Amo has received research grants awarded to her institution from Companies BMS, Gilead, ViiV and epidemiology teaching fees from ViiV, Gilead and MSD Dr Julia del Amo National
More informationHIV, HBV and HCV testing policy experiences and lessons learned.
HIV, HBV and HCV testing policy experiences and lessons learned. Contents HIV and viral hepatitis: distinct epidemics at different stages of evolution Epidemiology: transmission, prevalence, incidence
More informationThe New HIV Epidemic Challenges: Policy, Politics, and Poor Patients
The New HIV Epidemic Challenges: Policy, Politics, and Poor Patients John T. Carlo, MD, MS Chief Executive Officer AIDS ARMS, INC. https://twitter.com/jtcarlo Conflict of Interest None 2 Learning Objectives
More informationState of Alabama HIV Surveillance 2013 Annual Report Finalized
State of Alabama HIV Surveillance 2013 Annual Report Finalized Prepared by: Division of STD Prevention and Control HIV Surveillance Branch Contact Person: Allison R. Smith, MPH Allison.Smith@adph.state.al.us
More informationTrends in HIV Incidence and Prevalence in the United States
Trends in HIV Incidence and Prevalence in the United States Irene Hall, PhD, FACE 7th International Workshop on HIV Transmission Washington, DC, July 20, 2012 National Center for HIV/AIDS, Viral Hepatitis,
More information11/8/2016. The Challenge of HIV Treatment
You Mean I Have to Talk About...Sex? Trudy Larson, MD Professor and Director, School of Community Health Sciences Medical Director, Nevada AIDS Education and Training Center Nat l HIV/AIDS Strategy Goals
More informationUpdate on Biomedical Prevention. Thomas C. Quinn, MD, MSc
Update on Biomedical Prevention Thomas C. Quinn, MD, MSc Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health
More informationECDC update to the EU Commission Think Tank on HIV/AIDS
ECDC update to the EU Commission Think Tank on HIV/AIDS Andrew Amato Head of HIV, STI and V. Hepatitis programme, ECDC Luxembourg, 10-11 December 2013 Outline Main ECDC reports published since last Think
More informationFive Things to Know About Antiretroviral Therapy (ART) & HIV Prevention
Five Things to Know About Antiretroviral Therapy (ART) & HIV Prevention Five Things to Know: Essentials of HIV Prevention Webinar Series Webinar 3 Primary Care Development Corporation Five Things to Know:
More informationCascade of medical care to HIV-infected patients in Europe. Cristina Mussini
Cascade of medical care to HIV-infected patients in Europe Cristina Mussini UNAIDS: New HIV treatment target 90% of people tested 90% of people diagnosed with HIV on treatment 90% of people on treatment
More informationCombination HIV Prevention
Combination HIV Prevention Timothy Mastro, MD, FACP, DTM&H FHI 360, Durham, North Carolina, USA 7 th INTEREST Workshop, Dakar, Senegal 15 May 2013 Outline What Works for HIV Prevention? Highly Active
More informationAn Update on the US HIV Epidemic and Recent Strides in HIV Care
An Update on the US HIV Epidemic and Recent Strides in HIV Care Boca Raton Regional Hospital Grand Rounds 05/24/2016 Kenneth Poon MD ABIM Infectious Diseases Assoc Prog Dir Asst Prof of Clin Biomed Internal
More information2010 HIV Prevention Plan and HIV Prevention Section Update
2010 HIV Prevention Plan and HIV Prevention Section Update Grant Colfax, MD Director of HIV Prevention San Francisco Department of Public Health San Francisco Health Commission April 6, 2010 HIV Prevention
More informationHIV Clinical Update- HIV prevention
HIV Clinical Update- HIV prevention 18 th Australian and New Zealand Conference on Haemophilia and Rare Bleeding Disorders, Melbourne October 13 th 2017 Edwina Wright Disclosures None in the past 12 months
More informationWhy are the targets a game-changer? What is the Fast-Track Cities Initiative and its connection to ?
Frequently Asked Questions about 90-90-90 Targets, the HIV Care Continuum, the Updated National HIV AIDS Strategy (NHAS), and the Fast-Track Cities Initiative What is the origin of the 90-90-90 targets?
More informationClinical Infectious Diseases Advance Access published June 16, Age-Old Questions: When to Start Antiretroviral Therapy and in Whom?
Clinical Infectious Diseases Advance Access published June 16, 2015 1 Age-Old Questions: When to Start Antiretroviral Therapy and in Whom? Rochelle P. Walensky, Martin S. Hirsch From the Division of Infectious
More informationThresia Sebastian MD, MPH University of Colorado, Denver Global Health Disasters Course October 2016
Thresia Sebastian MD, MPH University of Colorado, Denver Global Health Disasters Course October 2016 1 Objectives of today s lecture Describe global goals in the fight against HIV Review the epidemiology
More informationMobility in Africa: human rights and the HIV care cascade
Population Mobility: Challenges for Universal HIV Testing and Treatment Mobility in Africa: human rights and the HIV care cascade Joseph Larmarange Institut de Recherche pour le Développement (IRD) Preliminary
More informationPrEP (Pre-Exposure-Prophylaxis) for sub-saharan African migrants in Europe?
PrEP (Pre-Exposure-Prophylaxis) for sub-saharan African migrants in Europe? OFFERING PrEP TO ALL GROUPS AT INCREASED RISK FOR HIV. A RESEARCH AGENDA Jasna Loos HIV and Sexual Health Department of Public
More informationLessons learnt from other screening programmes : the case of HIV screening
Lessons learnt from other screening programmes : the case of HIV screening Caroline Semaille, Stéphane Le Vu, Françoise Cazein, Christine Larsen, Josiane Pillonel, Florence Lot HIV/AIDS-STI-Hepatitis C
More informationTerapia come prevenzione e ruolo del community viral load (CVR) Andrea Antinori INMI L. Spallanzani IRCCS, Roma
Terapia come prevenzione e ruolo del community viral load (CVR) Andrea Antinori INMI L. Spallanzani IRCCS, Roma Transmission Rate per 100 Person-Yrs ART for HIV Prevention: The Hypothesis The quantity
More informationStigma and HIV. Maria E. Alvarez, MPA. LEAD PUBLIC HEALTH ADVISOR Team Lead, Capacity Building Branch Partnerships Team
Stigma and HIV Maria E. Alvarez, MPA LEAD PUBLIC HEALTH ADVISOR Team Lead, Capacity Building Branch Partnerships Team 3 rd Annual International Conference on Stigma Howard University Blackburn Center Washington
More informationPREVENTION OF HIV IN THE TIMES OF PREP. Daniela Chiriboga, MD Florida Department of Health in Polk County
PREVENTION OF HIV IN THE TIMES OF PREP Daniela Chiriboga, MD Florida Department of Health in Polk County MAKING THE CASE FOR PREVENTION The Epidemic in Florida Population in 2014: 19.6 million (3 rd in
More informationHIV Testing and HIV Prevention
HIV Testing and HIV Prevention Five Things to Know: Essentials of HIV Prevention Webinar 2 Primary Care Development Corporation Five Things to Know: Essentials of HIV Prevention Social Marketing and HIV
More informationPrEP efficacy the evidence
PrEP efficacy the evidence Dr Michael Brady Consultant, HIV and Sexual Health King s College Hospital, London Medical Director Terrence Higgins Trust PrEP Pre-exposure prophylaxis Tenofovir and emtricitabine
More informationHUMAN SERVICES COMMISSION JANUARY 8, 2019 UNFINISHED BUSINESS HIV ZERO INITIATIVE END OF YEAR 2 EVALUATION REPORT
HUMAN SERVICES COMMISSION JANUARY 8, 2019 UNFINISHED BUSINESS SUBJECT: INITIATED BY: HIV ZERO INITIATIVE END OF YEAR 2 EVALUATION REPORT HUMAN SERVICES AND RENT STABILIZATION DEPARTMENT David Giugni, Social
More informationSexually Transmitted Infections in Vulnerable Groups. Kevin Rebe
Sexually Transmitted Infections in Vulnerable Groups Kevin Rebe Definition: Key Populations Key populations are: Defined groups who, due to specific higher-risk behaviours, are at increased Men risk who
More informationWhen to start: guidelines comparison
The editorial staff When to start: guidelines comparison The optimal time to begin antiretroviral therapy remains a critical question for the HIV field, and consensus about the appropriate CD4+ cell count
More informationPrEP and Behavioral Strategies for HIV Prevention. Douglas Krakower, MD January 30, 2014
PrEP and Behavioral Strategies for HIV Prevention Douglas Krakower, MD January 30, 2014 Potential Competing Interests Dr. Krakower: investigator-initiated research regarding HIV prevention National Institutes
More information2016 NYS HIV Quality of Care Review
2016 NYS HIV Quality of Care Review A new way forward in four parts Bruce Agins, MD, MPH Medical Director NYSDOH AIDS Institute December 15, 2016 Ending the Epidemic: update! A 3-Point plan announced by
More informationFrom Africa to Georgia: What We Have Learned From the Treatment for All Initiative
From Africa to Georgia: What We Have Learned From the 90-90-90 Treatment for All Initiative Carlos del Rio, MD Professor of Global Health Rollins School of Public Health Professor of Medicine Emory University
More informationIllustrating HIV/AIDS in the United States Update
Illustrating HIV/AIDS in the United States 2016 Update About AIDSVu AIDSVu is a compilation of interactive, online maps that allows users to visually explore the HIV epidemic in the U.S. alongside critical
More informationDr Marta Boffito Chelsea and Westminster Hospital, London
Dr Marta Boffito Chelsea and Westminster Hospital, London Speaker Name Statement Dr Marta Boffito has received travel and research grants from and has been an advisor for Janssen, Roche, Pfizer, ViiV,
More informationECDC and Spanish Ministry of Health workshop:
ECDC and Spanish Ministry of Health workshop: Improving the monitoring of HIV among migrant populations in Europe, Madrid, 3-4 October 2013 Teymur Noori EU Commission Thank Tank on HIV/AIDS Luxembourg,
More informationBiomedical Prevention Update Thomas C. Quinn, M.D.
Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global
More informationQ and A - the PARTNER Study: new results from PARTNER 2
Q and A - the PARTNER Study: new results from PARTNER 2 1. Study results What is the PARTNER Study? The PARTNER study is an international two-phase study that looked at whether HIV transmission occurs
More informationMoving beyond condoms to prevent HIV transmission. Are you Prepared for HIV PrEP?
Moving beyond condoms to prevent HIV transmission Are you Prepared for HIV PrEP? The Issues New HIV infections in the US continue Vast majority of infections are sexually acquired Condoms work but are
More informationART and Transmission. Martin Fisher. Brighton and Sussex University Hospitals, UK
ART and Transmission Martin Fisher Brighton and Sussex University Hospitals, UK 11th Advanced HIV Course Aix-en-Provence 2013 New HIV diagnoses by exposure group: United Kingdom, 2002 2011 1 Predicted
More informationTHIRD JOINT CONFERENCE OF BHIVA AND BASHH Dr Laura Waters. Mortimer Market Centre, London. 1-4 April 2014, Arena and Convention Centre Liverpool
THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Dr Laura Waters Mortimer Market Centre, London 1-4 April 2014, Arena and Convention Centre Liverpool THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014 Dr Laura
More informationEnding the Epidemic in New York State
Ending the Epidemic in New York State HIV Quality of Care Clinical and Consumer Advisory Committee Joint Meeting September 8, 2015 September 10, 2015 Defining the End of AIDS Goal Reduce from 3,000 to
More informationKey issues for HIV testing and
Key issues for HIV testing and counselling in Europe Martin C Donoghoe Programme Manager HIV/AIDS, STI &Viral Hepatitis Programme WHO Europe Key issues for HIV testing & counselling in Europe HIV epidemics
More informationArizona State Office of Rural Health Webinar Series
Arizona State Office of Rural Health Webinar Series Mute your phone &/or computer microphone Time is reserved at the end for Q&A Please fill out the post-webinar survey Webinar is being recorded Recording
More informationCulturally Relevant Linkages to Care
Culturally Relevant Linkages to Care Matt Ignacio, MSSW Tohono O'odham Jamie Folsom, MS Oklahoma Choctaw Project Managers - National Native American AIDS Prevention Center National Native American AIDS
More informationWOMEN & HIV: A GLOBAL UPDATE. Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society
WOMEN & HIV: A GLOBAL UPDATE Deanna Kerrigan, PhD, MPH Associate Professor Health, Behavior & Society Objectives Review the current global burden of HIV among women Trends and progress to date Groups with
More informationThe Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018
The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and
More informationMoving PrEP Forward. Where We Are & Where We Need to Go. Christopher Hurt, MD Assistant Professor of Medicine Division of Infectious Diseases
Moving PrEP Forward Where We Are & Where We Need to Go Christopher Hurt, MD Assistant Professor of Medicine Division of Infectious Diseases Overview Recent study results & some context o o o Epidemiology
More informationCommunity-Based TasP Trials: Updates and Projected Contributions. Reaching the target: Lessons from HPTN 071 (PopART) Sarah Fidler
Community-Based TasP Trials: Updates and Projected Contributions Reaching the 90-90-90 target: Lessons from HPTN 071 (PopART) Sarah Fidler Cascade of Care: Sub-Saharan Africa HIV test +ve in past 12 m
More informationART for prevention the task ahead
ART for prevention the task ahead Dr Teguest Guerma WHO/HQS WHO's role and vision Status of the epidemic Overview Progress and challenges in treatment and prevention scale up ART for prevention Questions
More informationDominic Chow, MD, PhD, MPH, Hawaii Center for AIDS Kunane Dreier, Prevention, Life Foundation Kekoa Kealoha, Hawaii Island HIV/AIDS Foundation Alexis
Dominic Chow, MD, PhD, MPH, Hawaii Center for AIDS Kunane Dreier, Prevention, Life Foundation Kekoa Kealoha, Hawaii Island HIV/AIDS Foundation Alexis Charpentier, Harm Reduction Services Branch, Hawaii
More informationPrEP for HIV prevention. Pep Coll AIDS Research Institute-IrsiCaixa Fight AIDS Foundation BCN Checkpoint
PrEP for HIV prevention Pep Coll AIDS Research Institute-IrsiCaixa Fight AIDS Foundation BCN Checkpoint DISCLOSURES I have received a research grant from Gilead Sciences awarded to my institution I have
More informationHigh Impact HIV Prevention Services and Best Practices
High Impact HIV Prevention Services and Best Practices David W. Purcell, JD, PhD Deputy Director for Behavioral and Social Science Division of HIV/AIDS Prevention Centers for Disease Control and Prevention
More informationPRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS. Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program
PRE-EXPOSURE PROPHYLAXIS FOR HIV: EVIDENCE AND GENDER CONSIDERATIONS Jean R. Anderson M.D. Director, Johns Hopkins HIV Women s Health Program Disclosures None Objectives Review the evidence regarding the
More informationWHO Global Health Sector Strategies HIV; Viral Hepatitis; Sexually Transmitted Infections
Common structure Universal Health Coverage SDGs Cascade of services Vision, Goals and Targets Costed Actions WHO Global Health Sector Strategies 2016-2021 HIV; Viral Hepatitis; Sexually Transmitted Infections
More informationStrengthening Linkages: why & how to connect our dots
Strengthening Linkages: why & how to connect our dots Sophy S. Wong, MD Medical Director, Bay Area & North Coast AETC Associate Clinical Professor of Medicine, UCSF Workshop objectives Why linkage matters
More informationWhy isn t TasP already working?
Why isn t TasP already working? Some more considerations Gus Cairns Editor, HIV Treatment Update, Preventing HIV and www.aidsmap.com HPTN 052: confidence intervals 29 September 2011 SW regional conference
More informationHIV Screening in Behavioral Health Settings: The Need is Clear
HIV Screening in Behavioral Health Settings: The Need is Clear Alyssa A. Bittenbender, MPH Program Director, Arizona AIDS Education and Training Center University of Arizona College of Medicine MISSION
More informationPrEP: Getting to the Tipping Point
PrEP: Getting to the Tipping Point Harvey J Makadon, MD The National LGBT Health Education Center, The Fenway Institute Professor of Medicine, Harvard Medical School April 15, 2016 Continuing Medical Education
More informationNHS England. Evidence review: Immediate initiation of Anti-Retroviral-Therapy
NHS England Evidence review: Immediate initiation of Anti-Retroviral-Therapy 1 NHS England Evidence review: Immediate initiation of anti-retroviral therapy First published: October 2016 Updated: Not applicable
More informationGetting to zero HIV new infections in Asia and the Pacific region: Possible or impossible dream?
Getting to zero HIV new infections in Asia and the Pacific region: Possible or impossible dream? Steven J. Kraus Director UNAIDS Regional Support Team, Asia and the Pacific Timothy D. Mastro Director,
More informationPrEP: Pre Exposure Prophylaxis
PrEP: Pre Exposure Prophylaxis Lyn Stevens, NP, MS, ACRN Deputy Director Office of the Medical Director NYS Department of Health, AIDS Institute Faculty Disclosure Lyn Stevens No relationships to disclose
More informationA Sex-informed Framework for HIV Prevention. Robert M. Grant, M.D., M.P.H. Betty Jean and Hiro Ogawa Endowed Investigator
A Sex-informed Framework for HIV Prevention Robert M. Grant, M.D., M.P.H. Betty Jean and Hiro Ogawa Endowed Investigator Disclosures Gilead Sciences donated study medication to US NIH for trials that I
More informationHIV Prevention. Recent Advances and Implications for the Caribbean
HIV Prevention Recent Advances and Implications for the Caribbean Chris Behrens, MD CCAS/CHART Conference Barbados, August 2010 Cases 200 180 160 140 120 100 80 60 40 20 0 Year HIV Cases AIDS Cases HIV
More informationHIV Prevention among Women
HIV Prevention among Women Assistant Professor of Medicine Division of Infectious Diseases Baylor College of Medicine Disclosures: Gilead Sciences - Scientific Advisory Board; Investigatorinitiated research
More informationThe role of Integrase Inhibitors during HIV prevention
The role of Integrase Inhibitors during HIV prevention Pep Coll AIDS Research Institute-IrsiCaixa Fight AIDS Foundation BCN Checkpoint 2nd Global HIV Clinical Forum: Integrase Inhibitors Paris July 22th
More informationColloque scientifique : L économie de la prévention Analysis of Cost-Effectiveness of HIV Prevention
Colloque scientifique : L économie de la prévention Analysis of Cost-Effectiveness of HIV Prevention Julia Walsh MD, MSc Professor School of Public Health University of California Berkeley Objectives Cost-effectiveness
More informationHPTN 071 (PopART) Population Effects of Antiretroviral Therapy to Reduce HIV Transmission
HPTN 071 (PopART) Population Effects of Antiretroviral Therapy to Reduce HIV Transmission TWEET LIVE #HPTN071 DIAL IN NUMBER FOR AUDIO: 1-866-740-1260 BROADCAST AUDIO CODE: 4011527 PLEASE USE THE CHAT
More informationHIV Viral Suppression, 37 States and the District of Columbia, 2014
DOI 10.1007/s10900-017-0427-3 ORIGINAL PAPER HIV Viral Suppression, 37 States and the District of Columbia, 2014 Kristen L. Hess 1 H. Irene Hall 1 Published online: 18 September 2017 Springer Science+Business
More informationModernization of North Carolina s HIV control measures
Modernization of North Carolina s HIV control measures North Carolina Division of Public Health Victoria Mobley, MD MPH Evelyn Foust, MPH CPM Agenda Introduction Summary of scientific evidence used to
More information